TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00779038
Drug: Fentanyl ITS
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mcg per 10 minutes of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 3.2 milligram (80 doses) within a 24 hour period from an ITS. Total duration of treatment will be 72 hours.
Study: NCT02225886
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg of intravenous ascorbic acid will be given 3 times a week, postdialysis, in 100 mL saline solution, except for the dialysis sessions when iv iron is administered
Study: NCT02971696
Drug: Best Supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liver Support, pain management
Study: NCT01192763
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT04407507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days
Study: NCT02958163
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug-eluting Bead for Trans Arterial Chemo-Embolization will be loaded with Doxorubicin.
Study: NCT01731691
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment in HIV disease will be compared with Prolastin-C treatment in HIV disease and no treatment in uninfected volunteers.
Study: NCT01645280
Drug: Placebo + methotrexate (MTX) (Group 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
Study: NCT02723162
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT02601885
Drug: ABT-555
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Infusion
Study: NCT03576677
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo solution will be prepared by adding 10 mL of 5% dextrose to a vial containing Soluvit (vitamin B) under aseptical conditions. 5 mL of this solution is then added to 245 mL of isotonic sodium chloride solution.~5% dextrose and vitamin B are added to ensure yellow coloring indistinguishable from the active drug (levosimendan).~Patients will receive a 6 hours infusion of this study drug. Infusion rate will be calculated in similar fashion to the levosimendan group.
Study: NCT02924753
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
Study: NCT04046484
Drug: PMZ-1620 along with standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
Study: NCT02371369
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule matching pexidartinib capsule for oral administration
Study: NCT03607383
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin choice is done at the discretion of the treating physician for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions, for 8 weeks
Study: NCT00463450
Drug: Gynodian® Depot (BAY86-5032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection monthly
Study: NCT00463450
Drug: BAY86-4980
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally
Study: NCT00733265
Drug: AZD6140
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose
Study: NCT02477865
Drug: PEX168(100µg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100µg,Subcutaneous injection,once a week. continued for 52 weeks
Study: NCT02477865
Drug: PEX168(200µg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200µg,Subcutaneous injection,once a week. continued for 52 weeks
Study: NCT02477865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then use PEX168 100µg or 200µg qw sc.for 28 weeks.
Study: NCT04039828
Drug: Zinc Sulfate Dispersible Tablet 20 mg (Elemental Zinc 20 mg as Zinc Sulfate Monohydrate / Tablet)
Normalized name: zinc sulfate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half of the tablet (10 mg) for 3 to 6 months old children and one tablet (20 mg) daily for \> 6 to 59 months old children. The tablet will be dissolved in a teaspoon of safe water or breast milk and administered once daily for 10 days.
Study: NCT00658333
Drug: Enteric-coated Mycophenolate Acid (EC-MPA)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04568174
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A standard PBS solution, pH 7.4, composed of disodium hydrogen phosphate dodecahydrate, potassium dihydrogen phosphate, sodium chloride, and water for injection
Study: NCT01275248
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet to match the experimental interventions
Study: NCT02137629
Drug: Vidaza®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The recommended starting dose for the first treatment for all patients regardless of baseline hematology values is Vidaza® 75mg/m2 subcutaneous(SC) injection or intravenous (IV) infusion, daily for 7 days.
Study: NCT03021187
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide placebo administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
Study: NCT03658720
Drug: 200 mg Ibuprofen acid orodispersible tablet
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: orodispersible tablet
Study: NCT02946294
Drug: Bupivacaine 0.25% with epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01914133
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given prior to meal the standardized meal
Study: NCT00083824
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 pills/day QID for 3 years
Study: NCT03466346
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine is a selective serotonin reuptake inhibitor that is FDA approved for the treatment of depression. Compared to placebo, fluoxetine is more likely to produce symptom response for MDD. Despite the interim development of many other antidepressants since the development of fluoxetine, it remains a first line treatment for depression.
Study: NCT04592692
Drug: PEGylated Liposome (PEGLip)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous co-administration of PEGLip with Simoctocog alfa
Study: NCT01964365
Drug: Cresto 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, rosuvastatin 20mg
Study: NCT01112215
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial dose of 2-2.5 mg/kg (according to TMTP levels) for 6 months according the severity of the flare with progressive tapering if complete remission has been obtained
Study: NCT01112215
Drug: Enteric-Coated Mycophenolate Sodium
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial dose of 1440 mg/day for 6 months to be tapered progressively if complete remission had been obtained
Study: NCT01094483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00206518
Drug: Adriamycin/Cytoxan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adriamycin/Cytoxan
Study: NCT00206518
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery.
Study: NCT00077233
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT02697240
Drug: Intravenous citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous citrulline at a bolus dose of 20 mg/kg over 5 minutes and then continuous at a rate of 7 mg/kg/hour for the next 23 hours for the first 7 participants, and depending on safety and pharmacokinetic profile, increase or decrease the continuous rate to 9 or 5 mg/kg/hour for the next 7 participants.
Study: NCT00148590
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of 20 mg Memantine add-on to Risperidone vs Placebo add-on to Risperidone
Study: NCT02575664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch
Study: NCT00642616
Drug: Technosphere® Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technosphere® Insulin delivered with Gen 2 inhaler with doses individualized for each participant in combination with an antidiabetic regimen of insulin and/or oral antidiabetic agents
Study: NCT00642616
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type 1 diabetics: long-acting (basal) insulin plus rapid-acting insulin, or pre-mix insulin Type 2 diabetics: oral anti-diabetic medications with or without long-acting (basal) insulin
Study: NCT01696877
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide as a potent enhancer of immune responses to GVAX. cyclophosphamide is used as an immune suppressor in many autoimmune disorders.
Study: NCT03533790
Drug: DEP-Ru
Normalized name: estradiol cypionate / testosterone cypionate Injectable Solution [Dep Androgyn]
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Drug: ruxolitinib~* Drug: doxorubicin~* Drug: etoposide~* Drug: methylprednisolone
Study: NCT06673927
Drug: YZJ-1139
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose, 2mg, 5mg, 10mg, 20mg, 40mg, 60mg, 80mg
Study: NCT06673927
Drug: YZJ-1139
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple Dosing ，Each oral dose of 10 mg，20 mg，40 mg or 60 mg
Study: NCT06673927
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration
Study: NCT00928980
Drug: Optimal Medical Care
Normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic dose of antidepressant medication
Study: NCT01133639
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care
Study: NCT01133639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus standard of care
Study: NCT00918723
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01003249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg.
Study: NCT03421613
Drug: 3VM1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self treatment 3 times daily for 10 days
Study: NCT01378390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration will be preceded by localization and closure of the internal opening following Major Ambulatory Surgery standards. Subjects will be receiving one treatment cycle with placebo consisting of intralesional instillation of 5 ml saline solution. Patients without healing (complete fistula closure) following week 12 assessment will continue to receive standard of care until the primary assessment of fistula closure at week 24. Patients with incomplete fistula closure at week 24 will be offered the possibility of participating in a separate open-label, single arm study using the ASCs derived from the liposuction procedure.
Study: NCT01516450
Drug: GSK1550188 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV dose of belimumab 200 mg
Study: NCT03102736
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo saline
Study: NCT00862381
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: hemisuccinate d'hydrocortisone, 200mg per 24 hours, 48 hours of treatment
Study: NCT00862381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9%
Study: NCT01025778
Drug: Cyclophosphamide for remission induction
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03722680
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04097288
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT00884507
Drug: RO5313534
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg po daily for 24 weeks
Study: NCT00884507
Drug: RO5313534
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg po daily for 24 weeks
Study: NCT00884507
Drug: RO5313534
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg po daily for 24 weeks
Study: NCT03161418
Drug: KSP-910638G, 0.4 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (0.4 mg dose)
Study: NCT00809757
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 actuations)
Study: NCT01924325
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04679129
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT03156023
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection once every 2 weeks.
Study: NCT01496352
Drug: DFA-02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified release product containing gentamicin and vancomycin for application at the conclusion of surgery after closure of the fascia and prior to skin closure
Study: NCT01496352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFA-02 placebo
Study: NCT02433353
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Look-alike venlafaxine XR tablets containing no active drug
Study: NCT03161418
Drug: KSP-910638G, 1.2 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (1.2 mg dose)
Study: NCT01287585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: weekly, intramuscular, until disease progression or toxicity.
Study: NCT01438411
Drug: Cholic Acid
Normalized name: Cholic Acid
DrugBank: Cholic Acid (DB02659)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10-15 mg/kg body weight/day supplied in 50 or 250 mg Cholic Acid Capsules
Study: NCT04655586
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard of care heparin per institution (therapeutic or prophylactic regimen)
Study: NCT01464697
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator, taken as 3 round capsules at bedtime daily for 12 weeks
Study: NCT01050062
Drug: Hydrochlorothiazide 12.5mg
Normalized name: HYDROCHLOROTHIAZIDE 12.5MG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablet
Study: NCT01819961
Drug: MCT/LCT
Normalized name: lipid emulsion MCT/LCT (1:1)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03656640
Drug: Gammanorm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients already receiving Gammanorm will be observed over the course of 2 years every 3 months. Gammanorm will be given standard of care.
Study: NCT00865501
Drug: spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg per oral once daily
Study: NCT02410369
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following randomization, subjects with HLA-A\*2402 in the investigational arm will receive the subcutaneous administration of Placebo.
Study: NCT02677701
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500mg tablet over-encapsulated to match placebo
Study: NCT02677701
Drug: placebo (for azithromycin)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02677701
Drug: inhaled tobramycin
Normalized name: tobramycin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: clinically prescribed inhaled tobramycin used by subjects participating in the study
Study: NCT01849848
Drug: SyB L-0501
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: The administration of SyB L-0501 at 90 mg/m\^2/day by 60-minute intravenous infusion for 2 consecutive days followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 times. Dose reduction or discontinuation is permitted from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle.
Study: NCT02796144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebos will be administered for each drug.
Study: NCT03667677
Drug: Tandospirone + Amlodipine
Normalized name: Tandospirone
DrugBank: Tandospirone (DB12833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).
Study: NCT03971617
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablet
Study: NCT02453789
Drug: Alginate oligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of dry powder for inhalation (DPI)
Study: NCT02453789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02595203
Drug: [14C-pos 1]-Debio 1450 BES Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: A solution containing Debio 1450 bis ethanolamine salt (BES) radiolabelled with carbon-14 (14C) at position 1
Study: NCT02595203
Drug: [14C-pos 25]-Debio 1450 BES Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: A solution containing Debio 1450 BES radiolabelled with carbon-14 (14C) at position 25
Study: NCT03667677
Drug: Tandospirone placebo + Amlodipine placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The fourth group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).
Study: NCT00184054
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic Acid 1000 mg every other day for 25 days
Study: NCT01169870
Drug: Genexol-PM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment is given in the outpatient setting. Patients receive treatment every 3 weeks up to 6 cycles.
Study: NCT01985685
Drug: Thiamine
Normalized name: Thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg IV thiamine
Study: NCT00744367
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sc once weekly
Study: NCT02231203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 infusions, 2 ml/kg, one the night before operation and one the day after operation
Study: NCT01188798
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
Study: NCT00939172
Drug: TTP607
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.3 mg/m\^2 given by central venous catheter over 1-4 hours, each day for 5 days in a row, for a 15 day cycle.
Study: NCT00611130
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets twice daily for 9 weeks
Study: NCT03046238
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine
Study: NCT02017249
Drug: arginine in powder form
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02017249
Drug: Silica and cellulose placebo powder
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02553915
Drug: EPA 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid extracted from fish oil, 1 g/day
Study: NCT02553915
Drug: EPA 2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid extracted from fish oil, 2 g/day
Study: NCT02553915
Drug: EPA 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid extracted from fish oil, 4 g/day
Study: NCT03085732
Drug: Irrigation with Saline Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: During hysterectomy after vaginal cuff closure 500-1000 mL saline irrigation will be done.
Study: NCT00153166
Drug: placebo/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo orally three times daily
Study: NCT02660359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points